Related Experiment Videos
Control of Pseudomonas sepsis in mice with azlocillin combined with gentamicin
Abstract:
The antibacterial activity of azlocillin VUFB and gentamicin was tested in vivo. To mice with Pseudomonas sepsis the test substances were injected either alone or combined, and the mortality was assessed. The test substances were freeze dried injectable azlocillin and gentamicin (Pharmachim). Azlocillin was injected into mice either intravenously or intramuscularly in graduated doses of 50-500 mg/kg once daily. The therapeutic effect was assessed on the basis of survival of the treated mice. Our expectation of a potentiated effect of the azlocillin-gentamicin combination was confirmed. After intramuscular administration of azlocillin plus gentamicin 90% of the mice survived, in comparison with 40% only after either azlocillin or gentamicin alone.
Insights
Combining azlocillin and gentamicin demonstrated enhanced antibacterial activity against Pseudomonas sepsis in mice. This combination therapy significantly improved survival rates compared to individual treatments, confirming a potentiated therapeutic effect.
Area of Science:
- Pharmacology
- Infectious Diseases
- Microbiology
Background:
- Pseudomonas sepsis is a severe infection often requiring combination antibiotic therapy.
- Azlocillin and gentamicin are established antibiotics with known antibacterial properties.
- Evaluating synergistic effects of antibiotic combinations is crucial for optimizing treatment strategies.
Purpose of the Study:
- To investigate the in vivo antibacterial activity of azlocillin and gentamicin, alone and in combination.
- To assess the therapeutic efficacy of the azlocillin-gentamicin combination against Pseudomonas sepsis in a murine model.
- To determine if a potentiated effect exists when azlocillin and gentamicin are administered together.
Main Methods:
- The study utilized a murine model of Pseudomonas sepsis.
- Test substances, freeze-dried injectable azlocillin and gentamicin, were administered intravenously or intramuscularly.
- Graduated doses of 50-500 mg/kg were given once daily, with mortality assessed to determine therapeutic effect.
Main Results:
- The combination of azlocillin and gentamicin showed a significant survival rate of 90% in mice with Pseudomonas sepsis.
- Individual administration of azlocillin or gentamicin resulted in a lower survival rate of 40%.
- The results confirmed the expected potentiated antibacterial effect of the combined therapy.
Conclusions:
- The combination of azlocillin and gentamicin exhibits a potentiated therapeutic effect against Pseudomonas sepsis in vivo.
- Intramuscular administration of the azlocillin-gentamicin combination offers superior efficacy compared to monotherapy.
- This study supports the use of azlocillin-gentamicin combination therapy for treating Pseudomonas infections.